Blog Article

In this blog post, we highlight a recent study that uses high-resolution microscopy to describe the onion-like architecture of Lewy bodies. Could these new insights change how we view Parkinson's disease pathology?

This webinar provides an overview of discovery and validation of biomarkers, such as α-Synuclein, that could serve as indicators of pathogenic process and be used to evaluate the efficacy of therapies for Parkinson's disease.

We explore new research that suggests Parkin participates in both ubiquitin-proteasomal degradation and redox biology. Learn how scientists used novel reagents to explain how Parkin dysfunction drives Parkinson’s disease.

In the first post of our COVID-19 blog series, we highlight the most recent findings on the genome and origins of SARS-CoV-2, and discuss how this research has spurred the development of novel therapies.

End your week by participating in one of our contests on Facebook, Twitter, or Instagram for a 500 or 1000 piece puzzle. Contests end Tuesday. Click on the social media icons below to make the social distancing experience a little easier.

BioLegend is ready to collaborate with your organization to help you accelerate the development of diagnostic tests, therapeutics, and vaccines for SARS-CoV-2. Please tell us how we can support your work.